Integra Lifesciences Hldgs Cp Stock Price, News & Analysis

Halda Therapeutics, a biotech company developing RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics for cancer, has appointed Christian Schade as President, CEO, and Board member. Schade brings over 20 years of pharma and biotech industry experience, including leadership in clinical pipeline development and value-creating deals. Tim Shannon continues as Board Chairman.

Schade's appointment comes as Halda prepares to enter clinical trials, with the first RIPTAC therapeutic expected to begin trials in the first half of 2025. The company is focusing on developing therapies for prostate and breast cancer. Schade's previous roles include CEO of Aprea Therapeutics, Growth Partner at Flagship Pioneering, and executive positions at Novira, Omthera Pharmaceuticals, and Medarex.

Integra LifeSciences (NASDAQ: IART), a leading global medical technology company, has announced its participation in the 22nd Annual Morgan Stanley Healthcare Conference. Lea Knight, the company's chief financial officer, is scheduled to present on September 6, 2024, at 10:45am ET.

The presentation will be accessible via a live webcast on Integra LifeSciences' investor relations website. This event provides an opportunity for investors and analysts to gain insights into the company's recent developments, financial performance, and future outlook within the healthcare technology sector.

Integra LifeSciences' participation in this prestigious conference underscores its commitment to engaging with the investment community and showcasing its position in the medical technology market.

Integra LifeSciences (NASDAQ: IART), a global medical technology leader, has announced its participation in the 2024 Wells Fargo Healthcare Conference. Lea Knight, the company's chief financial officer, is scheduled to present on September 4, 2024, at 1:30 PM ET.

Investors and interested parties can access a live webcast of the presentation through Integra's investor relations website. This event provides an opportunity for stakeholders to gain insights into the company's current status and future prospects directly from its financial leadership.

The presentation at this prestigious healthcare conference underscores Integra's commitment to transparency and engagement with the investment community, potentially impacting its market position and stock performance.

Integra LifeSciences (NASDAQ: IART) has released its third Environmental, Social and Governance (ESG) report, highlighting the company's 2023 performance and ongoing efforts in line with its ESG strategy. Key achievements include:

Environmental: Recalculated Scope 1, 2, and 3 emissions and partnered with external consultants to identify energy reduction opportunities.

Social: Enhanced diversity and inclusion efforts by adding a new employee resource group and supporting diverse college students and graduates.

Governance: Revised Code of Conduct and strengthened anti-bribery and corruption programs.

The report aligns with the Global Reporting Index and Sustainability Accounting Standards Board Index, demonstrating Integra's commitment to creating healthier people, workplaces, and world.

Integra LifeSciences (NASDAQ: IART) reported Q2 2024 financial results with revenues of $418.2 million, up 9.7% on a reported basis and 2.3% organically. The company reported a GAAP loss per share of $(0.16), compared to $0.05 in the prior year, and adjusted EPS of $0.63, down from $0.71. Integra updated its full-year 2024 guidance, projecting revenues of $1.609-$1.629 billion and adjusted EPS of $2.41-$2.57. The revised outlook reflects temporary shipping holds and investments in quality system improvements. Key highlights include:

- Early integration success with Acclarent ENT acquisition
- Plans to relaunch SurgiMend and PriMatrix at new facility in 2026
- Received PMA approvable notification for SurgiMend
- Implementing compliance master plan to address quality issues

Integra LifeSciences (Nasdaq: IART) has announced plans to restart manufacturing of PriMatrix® and SurgiMend® at its new facility in Braintree, Massachusetts, expected to be operational in the first half of 2026. The company has decided to consolidate operations at the new Braintree site instead of restarting production at its Boston facility. This decision follows a reassessment of plans after receiving third-party audit findings for the Boston site in March.

The new 100,000 square foot state-of-the-art facility in Braintree offers advantages such as improved quality systems, efficient process flows, and capacity for future growth. Integra will temporarily use the Boston site for product and process development to support the transition. The company remains committed to bringing PriMatrix and SurgiMend back to market and achieving pre-market approval for SurgiMend PRS in implant-based breast reconstruction.

Integra LifeSciences Holdings (NASDAQ: IART), a leading global medical technology company, has announced it will release its second quarter 2024 financial results on Monday, July 29, 2024, before the market opens. The company's management team will host a conference call at 8:30 a.m. ET on the same day to discuss the results.

A live webcast of the conference call will be available on the Investors section of Integra's website at investor.integralife.com. Interested participants can register to receive dial-in details and an individual pin for the call. Integra recommends joining the call 10 minutes before it starts. A webcast replay will be available on the company's Investors section following the call.

Integra LifeSciences Holdings (NASDAQ: IART), a prominent medical technology company, announced that its CFO, Lea Knight, will present at the 2024 Bank of America Healthcare Conference on May 14, 2024, at 4:40pm ET. The presentation will be livestreamed on the company's investor relations website.

Integra LifeSciences Holdings reported first quarter 2024 financial results, with revenues of $368.9 million declining 3.1% on a reported basis and 2.5% on an organic basis compared to the prior year. GAAP earnings per share were $(0.04), while adjusted earnings per share were $0.55. The company completed the acquisition of Acclarent, Inc., updating full-year revenue guidance to a range of $1.672 billion to $1.687 billion.